Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05IYA
|
|||
| Former ID |
DIB010634
|
|||
| Drug Name |
MEDI3902
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Ventilator-associated pneumonia [ICD-11: PK81.0] | Phase 2 | [1] | |
| Pseudomonas infection [ICD-11: 1B92; ICD-10: A24, A24.0] | Phase 1 | [2] | ||
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Pseudomonas PcrV protein type III (Pseudo pcrV) | Target Info | . | [3] |
| Pseudomonas Psl exopolysaccharide (Pseudo pslG) | Target Info | . | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02696902) Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects | |||
| REF 2 | ClinicalTrials.gov (NCT02255760) Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults. U.S. National Institutes of Health. | |||
| REF 3 | A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.